161 related articles for article (PubMed ID: 34044120)
1. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
[TBL] [Abstract][Full Text] [Related]
3. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J
Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.
Yao H; Xu F; Wang G; Xie S; Li W; Yao H; Ma C; Zhu Z; Xu J; Xu S
Eur J Med Chem; 2019 Apr; 167():485-498. PubMed ID: 30784881
[TBL] [Abstract][Full Text] [Related]
8. Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.
Kim HS; Hong M; Lee SC; Lee HY; Suh YG; Oh DC; Seo JH; Choi H; Kim JY; Kim KW; Kim JH; Kim J; Kim YM; Park SJ; Park HJ; Lee J
Eur J Med Chem; 2015 Nov; 104():157-64. PubMed ID: 26457742
[TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
Park M; Jung E; Park JM; Park S; Ko D; Seo J; Kim S; Nam KD; Kang YK; Farrand L; Hoang VH; Nguyen CT; La MT; Nam G; Park HJ; Ann J; Lee J; Kim YJ; Kim JY; Seo JH
Theranostics; 2024; 14(6):2442-2463. PubMed ID: 38646654
[No Abstract] [Full Text] [Related]
10. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
11. Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells.
Piven YA; Yastrebova MA; Khamidullina AI; Scherbakov AM; Tatarskiy VV; Rusanova JA; Baranovsky AV; Zinovich VG; Khlebnicova TS; Lakhvich FA
Bioorg Med Chem; 2022 Jan; 53():116521. PubMed ID: 34844036
[TBL] [Abstract][Full Text] [Related]
12. A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer.
Park JM; Kim YJ; Park S; Park M; Farrand L; Nguyen CT; Ann J; Nam G; Park HJ; Lee J; Kim JY; Seo JH
Mol Cancer; 2020 Nov; 19(1):161. PubMed ID: 33218356
[TBL] [Abstract][Full Text] [Related]
13. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
14. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
Oh SH; Woo JK; Yazici YD; Myers JN; Kim WY; Jin Q; Hong SS; Park HJ; Suh YG; Kim KW; Hong WK; Lee HY
J Natl Cancer Inst; 2007 Jun; 99(12):949-61. PubMed ID: 17565155
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
[TBL] [Abstract][Full Text] [Related]
18. Alkaloid derivative ION-31a inhibits breast cancer metastasis and angiogenesis by targeting HSP90α.
Ni TW; Duan XC; Wang M; Jia MQ; Chen Y; Yu Y; Qin N; Duan HQ
Bioorg Chem; 2021 Oct; 115():105201. PubMed ID: 34329994
[TBL] [Abstract][Full Text] [Related]
19. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
[TBL] [Abstract][Full Text] [Related]
20. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
